Tiziana life sciences announces podium presentation at ad/pd of nasal anti-cd3 in alzheimer's disease

New york, march 05, 2024 (globe newswire) -- tiziana life sciences ltd. (nasdaq: tlsa) (“tiziana” or the “company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced that dr. howard weiner will present positive data of intranasal anti-cd3 monoclonal antibody in models of alzheimer's and parkinson's disease at ad/pd, march 5-9, 2024. ad/pd is the annual international conference on alzheimer's and parkinson's diseases and related neurological disorders in lisbon, portugal.
TLSA Ratings Summary
TLSA Quant Ranking